

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases* Manuscript NO: 91158 Title: Thymic carcinoid with Multiple bone metastasis: a case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 07712490

Position: Peer Reviewer

Academic degree:

Professional title:

Reviewer's Country/Territory: United States

Author's Country/Territory: China

Manuscript submission date: 2023-12-23

Reviewer chosen by: AI Technique

Reviewer accepted review: 2024-01-19 18:14

Reviewer performed review: 2024-01-29 15:47

Review time: 9 Days and 21 Hours

	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of this manuscript	 [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No creativity or innovation



Baishideng

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-399-1568 E-mail: office@baishideng.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	 [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This manuscript describes a clinical case-study of a patient diagnosed with metastatic atypical thymic carcinoid tumors who was treated with anlotinib for one year with intent to improve qualiity-of-life. After one year of treatment, observations of reduction in pain, decreased NSE index, and tumor shrinkage were used to support the use of this treatment regiment in the future. Minor comments: 1. Sporadic grammatical errors. Manuscript should be reviewed by a reader fluent in the English language. -Page 1 Abstract line 1-2, 7, 9. -Page 2 line 1-3,7-8. -Page 3 lines 4-5, 12-17. -Page 4 lines 3, 18-19, 22. -Page 5 lines 9, 13-14, -Page 6 line 13 -Page 7 line 12 -Page 10, Figure 2, line 1. 2. Add APUD, SCLC, ESCC to abbreviations list 3. Add arrows, and dates to all scan images. Add scale bar to H and E image. 4. What were the reported side effects, if any, of anlotinib? 5. Did the patient progress after 2.5 years or was contact lost after 2.5 years? 6. What metrics were used as a report of reduction in pain after treatment?